Cite
Mass spectrometry characterization of DOTA-Nimotuzumab conjugate as precursor of an innovative β− tracer suitable in radio-guided surgery.
MLA
Martelli, Claudia, et al. “Mass Spectrometry Characterization of DOTA-Nimotuzumab Conjugate as Precursor of an Innovative Β− Tracer Suitable in Radio-Guided Surgery.” Journal of Pharmaceutical & Biomedical Analysis, vol. 156, July 2018, pp. 8–15. EBSCOhost, https://doi.org/10.1016/j.jpba.2018.03.018.
APA
Martelli, C., Marzano, V., Marini, F., Scotognella, T., Fratoddi, I., Venditti, I., Rotili, D., Solfaroli-Camillocci, E., Collamati, F., Mancini-Terracciano, C., Morganti, S., Maccora, D., Faccini, R., Cartoni, A., Giordano, A., & Castagnola, M. (2018). Mass spectrometry characterization of DOTA-Nimotuzumab conjugate as precursor of an innovative β− tracer suitable in radio-guided surgery. Journal of Pharmaceutical & Biomedical Analysis, 156, 8–15. https://doi.org/10.1016/j.jpba.2018.03.018
Chicago
Martelli, Claudia, Valeria Marzano, Federica Marini, Teresa Scotognella, Ilaria Fratoddi, Iole Venditti, Dante Rotili, et al. 2018. “Mass Spectrometry Characterization of DOTA-Nimotuzumab Conjugate as Precursor of an Innovative Β− Tracer Suitable in Radio-Guided Surgery.” Journal of Pharmaceutical & Biomedical Analysis 156 (July): 8–15. doi:10.1016/j.jpba.2018.03.018.